Propensity Matched Study of Outcomes of Teclistamab in relapsed/refractory Multiple Myeloma with Severe Renal Failure: A Multicenter Database Analysis

Key Points

• Patients receiving teclistamab showed improved outcomes compared to those without severe renal failure, indicating potential benefits.
• Across multiple centers, survival rates were notably higher in teclistamab-treated patients, emphasizing its efficacy in complex cases.
• Using a propensity matched study design, patient characteristics were balanced, enhancing the validity of the comparisons.
• Results call for further investigation into teclistamab's role in treating multiple myeloma patients with renal complications.